Related Experiment Video

Updated: Jul 3, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers

Sue-Anne Toh1, Daniel J Rader

  • 1Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania, 1 Maloney Building, 3400 Spruce Street, Philadelphia, PA 19104, USA. sue-anne.toh@uphs.upenn.edu

Expert Review of Cardiovascular Therapy
|August 1, 2008
PubMed

Insights

Obesity and diabetes drive cardiovascular disease. Targeting insulin resistance and lipid abnormalities, particularly through adipose tissue, is key for effective cardiometabolic risk reduction.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Endocrinology

Background:

  • Rising global rates of obesity and diabetes are exacerbating the cardiovascular disease epidemic.
  • Insulin resistance and dyslipidemia are critical clinical targets for cardiovascular risk reduction.
  • Current lipid management strategies often fall short of mandated clinical goals.

Purpose of the Study:

  • To highlight the challenges clinicians face in managing patients with insulin resistance and dyslipidemia.
  • To emphasize the need for comprehensive strategies addressing multiple metabolic defects.
  • To explore emerging perspectives on targeting adipose tissue for cardiometabolic risk reduction.

Main Methods:

  • This study is a review of current literature and emerging evidence.
  • It synthesizes information on the interplay between insulin resistance, dyslipidemia, and cardiovascular disease.
  • Focuses on the role of adipose tissue in these metabolic dysfunctions.

Main Results:

  • Adipose tissue plays a significant role in the relationship between insulin resistance and dyslipidemia.
  • Integrated approaches are necessary to manage the complex metabolic profiles of affected patients.
  • Current therapeutic strategies require enhancement to meet clinical goals for cardiovascular risk reduction.

Conclusions:

  • Effective cardiovascular risk reduction necessitates a comprehensive approach to managing insulin resistance and dyslipidemia.
  • Targeting adipose tissue represents a promising future therapeutic strategy.
  • Addressing the interconnections between metabolic defects is crucial for optimal patient outcomes.

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.